279 related articles for article (PubMed ID: 36389757)
1. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
2. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
4. Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC.
Li M; Zhang Y; Fan M; Ren H; Chen M; Shi P
BMC Med Genomics; 2021 Dec; 14(1):286. PubMed ID: 34861872
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
6. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
Yao Y; Wang J; Yang F; Gao W
Front Immunol; 2022; 13():924498. PubMed ID: 35844536
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy.
Ma J; Zhang M; Yu J
Front Oncol; 2022; 12():899925. PubMed ID: 35860577
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer.
Guo W; Huai Q; Zhou B; Guo L; Sun L; Xue X; Tan F; Xue Q; Gao S; He J
Cancer Immunol Immunother; 2023 Apr; 72(4):1029-1045. PubMed ID: 36308553
[TBL] [Abstract][Full Text] [Related]
9. [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.
Luo L; Li A; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Yunpeng Y; Li Z; Hong S
Immunol Res; 2023 Apr; 71(2):213-228. PubMed ID: 36434349
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
12. Construction and evaluation of a prognostic risk model of tumor metastasis-related genes in patients with non-small cell lung cancer.
Ding H; Shi L; Chen Z; Lu Y; Tian Z; Xiao H; Deng X; Chen P; Zhang Y
BMC Med Genomics; 2022 Sep; 15(1):187. PubMed ID: 36056349
[TBL] [Abstract][Full Text] [Related]
13. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
14. Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.
Wang Y; Zhu H; Zhang L; He J; Bo J; Wang J; Ding B; Ren M
J Cell Mol Med; 2024 May; 28(10):e18384. PubMed ID: 38760964
[TBL] [Abstract][Full Text] [Related]
15. Telomere length-related signature as a novel biomarker of prognosis and immune response in non-small cell lung cancer.
Liu XG; Li M; Mai SJ; Cai RJ
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1304-1319. PubMed ID: 35253187
[TBL] [Abstract][Full Text] [Related]
16. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.
Sheng H; Hao Z; Zhu L; Zeng Y; He J
BMC Cancer; 2022 May; 22(1):572. PubMed ID: 35606717
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.
Sun J; Zhang Z; Bao S; Yan C; Hou P; Wu N; Su J; Xu L; Zhou M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041817
[TBL] [Abstract][Full Text] [Related]
19. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
20. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
